Lixte Biotechnology Holdings Announces
Filing of a New Patent Application for Cancer Therapy Based on
Targeting a Biomarker by Novel Investigational Agents
EAST SETAUKET, N.Y., Aug. 19 /PRNewswire-FirstCall/ -- Lixte Biotechnology
Holdings, Inc. (OTC Bulletin Board: LIXT stock) announced today that the National
Institute of Neurological Disorders and Stroke (NINDS), National Institutes of
Health (NIH) and Lixte filed a joint patent application identifying a
biomarker, present in many common cancers, that is a target of drugs being
evaluated by Lixte and NINDS for the treatment of brain tumors.
Dr. John S. Kovach, President and CEO of Lixte, said, 'Studies with the
research team at the Molecular Pathogenesis Unit, Surgical Neurology Branch,
NINDS, identified a biomarker that appears to be preferentially targeted by
novel anti-cancer drugs currently being evaluated by NINDS and Lixte as new
treatments for human brain tumors. Molecular studies revealed that these
drugs alter the state of this biomarker in a way that leads to the death of
cancer cells. Since the biomarker appears to be important to the survival of
several human cancers in addition to brain cancers, studies will be done to
determine the effectiveness of targeting the biomarker in other tumor types
and as a guide to drug discovery of new anti-cancer compounds.'
Lixte Biotechnology Holdings Announces
Filing of a New Patent Application for the Use of Novel Compounds as
Potential Treatment for Neurodegenerative Diseases
EAST SETAUKET, N.Y., Aug. 12 /PRNewswire-FirstCall/ -- Lixte Biotechnology
Holdings, Inc. (OTC Bulletin Board: LIXT stock) announced today that it had filed a
patent application for the use of compounds the company is developing for
treatment of brain tumors as potential treatments for neurodegenerative
diseases including Alzheimer's and Parkinson's Disease.
Dr. John S. Kovach, President and CEO of Lixte, said, 'Lixte has developed
a series of novel compounds that inhibit the growth of common brain cancers of
adults and children in mouse models. We have now found that some variants of
these compounds have effects on brain cells that are believed to be
potentially useful for the treatment of common neurodegenerative brain
diseases. Since Lixte is focused primarily on developing anti-cancer drugs,
we are exploring partnerships with companies that have expertise and research
programs in the treatment of Alzheimer's Disease.'
Lixte Biotechnology Holdings Announces
That Novel Compounds Being Developed as Potential Treatments for Brain
Tumors Have Positive Activity in a Mouse Model of Human Pancreatic
Cancer
EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte Biotechnology
Holdings, Inc. (OTC Bulletin Board: LIXT stock) announced today that lead compounds
from each of two different types of drugs being developed as potential
treatment for specific types of brain cancers have activity against human
pancreatic cancers in a mouse model.
Dr. John S. Kovach, President and CEO of Lixte, said, 'Lixte previously
reported that lead compounds from each of two different classes of
pharmacologic agents have significant inhibitory activity against several
types of human cancers in the test tube and against brain cancers in animal
models. We have now found that two different lead compounds also have
statistically significant activity against human pancreatic cancer cells
growing in mice. These are early studies and there is no evidence that these
drugs are able to eliminate pancreatic cancers but rather slow their growth.
We are encouraged, however, that two classes of our drugs have activity
against this devastating cancer in addition to glioblastoma multiforme, the
most common and most malignant form of brain cancer.'
Lixte Biotechnology Holdings Announces
Extension of Its Cooperative Research and Development Agreement With
The National Institute of Neurological Disorders and Stroke, National
Institutes of Health, for Development of Anti-Brain Cancer Drugs
EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte Biotechnology
Holdings (OTC Bulletin Board: LIXT stock) announced today that the National
Institute of Neurological Disorders and Stroke (NINDS), National Institutes of
Health (NIH) and Lixte Biotechnology Holdings, Inc. extended their Cooperative
Research and Development Agreement (CRADA) to develop drugs for the treatment
of brain cancers. The CRADA, initiated in March 2006 was extended through
September 2009.
Dr. John S. Kovach, President and CEO of Lixte, said, 'The scientific
interaction with the research team at the Molecular Pathogenesis Unit (MPU),
Surgical Neurology Branch, (SNB), NINDS, has been highly productive and is a
good example of how government and private sector scientific organizations may
accelerate the drug development process. A novel biomarker of glioblastoma
multiforme, the most common and aggressive brain tumor of adults, discovered
at the MPU, SNB led to insights into potential vulnerability of this
devastating cancer to pharmacologic attack. Based on these insights, Lixte
synthesized two different types of anti-cancer drugs that target the
biomarker. In less than two years, working with the MPU, SNB under the CRADA,
Lixte has identified lead compounds of both types, which inhibit glioblastoma
multiforme in animal models. These novel compounds are now undergoing pre-
clinical evaluation of their pharmacologic characteristics, the first step in
the process of preparing an Investigational Drug Application (IND) to the FDA
for clinical evaluation.'
About the National Institute of Neurological Disorders and Stroke (NINDS),
(NIH):
NINDS (www.ninds.nih.gov) is a component of the National Institutes of
Health (NIH), and is the nation's primary supporter of biomedical research on
the brain and nervous system.
The National Institutes of Health (NIH) - The Nation's Medical Research
Agency - includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. It is the primary federal agency for
conducting and supporting basic, clinical and translational medical research,
and it investigates the causes, treatments, and cures for both common and rare
diseases. For more information about NIH and its programs, visit www.nih.gov.
Lixte Biotechnology Holdings Announces
That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was
Reported at the Annual Meeting of the American Association of Cancer
Research
EAST SETAUKET, N.Y., April 23 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings (OTC Bulletin Board: LIXT stock) announced today that Dr. Jie
Lu and Dr. Zhengping Zhuang of the Surgical Neurology Branch (SNB), National
Institute of Neurological Disorders and Stroke (NINDS), National Institutes of
Health (NIH) and its collaborator, Lixte Biotechnology Holdings. Inc.,
reported at the Annual Meeting of the American Association of Cancer Research
that its lead compound LB-1, one of a patent-pending proprietary series of
agents, has anti-cancer activity against human glioblastoma multiforme cells
in a mouse model of cancer. Glioblastoma multiforme is the most common and
aggressive brain tumor of adults.
The Dr. John S. Kovach, President and CEO of Lixte, said that the company
and SNB, NINDS are continuing to develop LB-1 and analogs of the compound for
the treatment of human brain cancers. Brain cancers pose a particular
challenge to the development of effective drug treatments. The brain is
protected by a physiological barrier that prevents the entry of many compounds
from the blood into brain tissue. To be effective, drugs must be designed
either to pass this barrier or be administered directly into the brain. 'We
are pursuing both strategies for the treatment of glioblastoma multiforme in a
rat model in which the cancer is growing in the brain,' said Dr. Kovach. 'We
want to be certain that we achieve drug delivery into the brain at
concentrations that inhibit these tumors.'
About Lixte Biotechnology Holdings, Inc.:
Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and
diagnostics company. Founded as a biomarker-diagnostics company in 2005,
Lixte develops new chemotherapy drugs targeting molecular abnormalities of
common human cancers.
About the National Institute of Neurological Disorders and Stroke (NINDS),
(NIH):
NINDS (www.ninds.nih.gov) is a component of the National Institutes of
Health (NIH), and is the nation's primary supporter of biomedical research on
the brain and nervous system.
The National Institutes of Health (NIH) - The Nation's Medical Research
Agency - includes 27 Institutes and Centers and is a component of the U.S.
Department of Health and Human Services. It is the primary federal agency for
conducting and supporting basic, clinical and translational medical research,
and it investigates the causes, treatments, and cures for both common and rare
diseases. For more information about NIH and its programs, visit www.nih.gov.
Forward-Looking Statements
This announcement contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, and Section 21E of the
Securities Exchange Act of 1934. For example, statements regarding the
Company's financial position, business strategy and other plans and objectives
for future operations, and assumptions and predictions about future product
demand, supply, manufacturing, costs, marketing and pricing factors are all
forward-looking statements. These statements are generally accompanied by
words such as 'intend,' anticipate,' 'believe,' 'estimate,' 'potential(ly),'
'continue,' 'forecast,' 'predict,' 'plan,' 'may,' 'will,' 'could,' 'would,'
'should,' 'expect' or the negative of such terms or other comparable
terminology. The Company believes that the assumptions and expectations
reflected in such forward-looking statements are reasonable, based on
information available to it on the date hereof, but the Company cannot provide
assurances that these assumptions and expectations will prove to have been
correct or that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements are
inherently subject to known and unknown risks and uncertainties. Actual
results or experience may differ materially from those expected or anticipated
in the forward-looking statements. Factors that could cause or contribute to
such differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar businesses,
and market and general economic factors. This discussion should be read in
conjunction with the condensed consolidated financial statements and notes
thereto included in Item 1 of the Quarterly Report on Form 10-QSB for the
quarter ending September 30, 2007.
For additional information Please see our Website: www.Lixte.com
For Investor Information, please contact: Frank Benedetto Mirador Consulting, Inc. 561-989-360
